Shilpa Medicare Share Price

Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs.  In addition, the company offers intermediates, peptides, biopolymers, biologics, contract development and manufacturing services, and formulations. Shilpa Medicare share price on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries. 

Shilpa Medicare stock price is influenced by various factors such as revenue growth, regulatory approvals from agencies like the USFDA, profit margins, research and development pipeline, and global demand for generic drugs. In the longer run, strategies related to capacity expansion, product launches, and growth in key therapeutic segments affect stock market sentiments. All these factors must be closely monitored to have an idea about the Shilpa Medicare stock price movements.  

Shilpa Medicare live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of Shilpa Medicare live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market. 

Furthermore, monitoring the Shilpa Medicare share͏ price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook. 

Shilpa Medicare Limited Company Fundamentals 

Shilpa Medicare Limited Company Background 

Shilpa Medicare Limited is one of India’s leading oncology-focused pharmaceutical manufacturers, with a strong global presence in active pharmaceutical ingredients (APIs), formulations, and contract development and manufacturing (CDMO) services. Established in 1987 in Raichur, Karnataka, the company commenced commercial production in 1989 and has since evolved into a knowledge-driven, research-oriented organisation catering to regulated markets worldwide. Shilpa Medicare has built a distinctive position in the highly competitive pharmaceutical landscape through its integrated capabilities spanning research, development, manufacturing, and commercialization of complex generic products. The company offers a diversified portfolio that includes generic APIs, intermediates, finished dosage formulations, and comprehensive CDMO solutions, addressing therapeutic areas such as oncology, anti-infectives, and specialty pharmaceuticals. With five manufacturing facilities, four of which are located in India, Shilpa Medicare adheres to stringent global quality standards and holds multiple international regulatory approvals. Its sustained focus on innovation, process excellence, and affordability has enabled the company to deliver advanced treatments at competitive costs. Guided by a commitment to quality, compliance, and continuous R&D investment, Shilpa Medicare continues to strengthen its role as a reliable global partner in the pharmaceutical and oncology manufacturing space. 

Shilpa Medicare Limited Company Product Lines 

• Active Pharmaceutical Ingredients (APIs): Oncology-focused and non-oncology APIs covering cardiovascular, CNS, antiviral, antifungal and other therapeutic segments. 
• Generic Formulations: Finished dosage forms including oral solids, injectables, suspensions and specialty formulations manufactured to global regulatory standards. 
• CDMO / Contract Development & Manufacturing Services: End-to-end services covering process development, scale-up, clinical supplies, commercial manufacturing and regulatory support. 
• Specialty & High-Potency Chemistry: High-potency APIs, peptide synthesis, continuous flow chemistry and complex chemistry solutions. 
• Biologics & Advanced Platforms: Emerging capabilities in biologics, polymers and novel drug delivery systems through dedicated subsidiaries. 

Shilpa Medicare Limited Company Revenue Model 

• API Sales Revenue: Sale of in-house manufactured APIs to global pharmaceutical companies. 
• Formulation Sales Revenue: Income from branded and generic finished formulations across domestic and international markets. 
• CDMO & Custom Manufacturing Revenue: Long-term development and manufacturing contracts with global innovators and generic players. 
• Export-Driven Earnings: A significant portion of total revenue is generated from regulated international markets. 

Shilpa Medicare Limited Geographic Presence 

• India: Manufacturing facilities located in Raichur, Jadcherla, Hyderabad, Hubli, Bangalore, Nacharam. 
• Global –.Doylestown, Pennsylvania 

Shilpa Medicare Limited Leadership and Brand Recognition 

Some of the key leaders of Shilpa Medicare as of January 2026 are 

• Omprakash Inani – Chairman 
• Vishnukant Chaturbhuj Bhutada – Managing Director 
• Sharath Reddy Kalakota – Whole-time Director 
• Hetal Madhukant Gandhi – Independent Director 
• Ashraf Loutfy Abdelhamid Allam – Independent Director 
• Dr. Anita Bandyopadhyay – Independent Woman Director 

Shilpa Medicare Limited Key Milestones 

• 1987: Incorporated as Shilpa Antibiotics Private Limited on 20 November; commenced operations as an API manufacturer at Raichur, Karnataka. 
• 1989: Started commercial production in November. 
• 1992: Installed production facilities for Sodium Methoxide. 
• 1993: Converted into a public limited company and renamed Shilpa Antibiotics Limited. 
• 2003: Name changed to Shilpa Medicare Limited on 17 February. 
• 2015: Executed successful product technology transfers; raised growth capital through preferential allotment to Tano Mauritius India FVCI II. 
• 2016: Sub-division of equity shares; Raichem Medicare Pvt. Ltd. commenced commercial production. 
• 2016–17: Launched generic versions of Vidaza Injection and Xeloda Tablets; raised funds via preferential allotment to TA FII Investors Limited. 
• 2017: Navya Biologicals Private Limited merged with the Company following NCLT approval. 
• 2019: Incorporated Shilpa Pharma Inc. as a wholly owned subsidiary in the USA. 
• 2019–20: Launched IBRUSHIL and Azacitidine in Europe; incorporated Shilpa Albumin and Shilpa Biologicals as wholly owned subsidiaries. 
• 2021: Launched Molshil; commissioned centralized Finished Dosage R&D Centre at Dabaspet; entered Sputnik V vaccine manufacturing agreement. 
• 2022: Commissioned ODF/TDS combo line; launched 12 formulations; expanded CDMO and R&D capabilities. 
• 2024: Launched first NDA product in the US; introduced High-Concentration Adalimumab in India; commissioned advanced biologics facility at Dharwad. 
• 2025: Secured European CEPs for peptide products; launched complex APIs; formed strategic partnership with Orion Corporation for Europe. 

Shilpa Medicare Limited Industry Perspective 

Shilpa Medicare operates within the global pharmaceutical industry, specifically in generic drugs, active pharmaceutical ingredients (APIs) and contract development & manufacturing (CDMO) services — a sector critical to affordable healthcare worldwide. India is the largest pharmaceutical market by volume and a leading global supplier of generics, fulfilling about 20 % of global generic drug supply and a large share of vaccine and medication needs across developed and emerging markets. The generic pharmaceuticals market was valued at approximately USD 437.9 billion in 2024 and is projected to more than double to USD 1,005.7 billion by 2035, growing at a CAGR of around 7.85 % between 2025 and 2035. Within this broader ecosystem, the API and CDMO segments are expanding rapidly, driven by patent expiries, outsourcing trends and increasing demand for both small-molecule and complex APIs. The global active pharmaceutical ingredient CDMO market is expected to reach about USD 209.85 billion by 2033, growing at an approximate CAGR of 7.85 % from 2025 to 2033. These trends underscore strong long-term growth in generic drug manufacturing, API production and outsourced development services, positioning companies like Shilpa Medicare to benefit from expanding global demand and rising healthcare needs. 

Shilpa Medicare is poised to benefit from rising global demand for affordable oncology and complex generic medicines. Increasing cancer prevalence, patent expiries, and the shift toward generics support its API and formulation portfolio. Its investments in biologics, CDMO services, and advanced drug delivery systems strengthen growth prospects across regulated markets while enhancing long-term revenue visibility and global competitiveness. 

Shilpa Medicare Limited Stock Market Presence: Listings & Index Representation 

Shilpa Medicare Limited is a well-established entity in the Indian stock market, listed on major exchanges such as NSE (SHILPAMED) and BSE (530661). The company was listed on the stock exchanges on May 23, 1995. Its inclusion in prominent indices like S&P BSE Healthcare, S&P BSE SmallCap, S&P BSE MidSmallCap, S&P BSE AllCap, BSE 1000, Nifty Microcap 250, and Nifty Total Market underscores the company’s standing in India’s pharmaceutical and healthcare sector. 

Shilpa Medicare’s stock price is closely watched by investors focused on the pharmaceutical sector. Its inclusion in these indices reflects its market capitalization, regulatory compliance, and operational scale in API and formulation manufacturing. Listing on the NSE and BSE ensures liquidity, while its presence in sectoral and broad-market indices links it to institutional investment flows and benchmark tracking within the healthcare sector. 

Shilpa Medicare Limited Stock Performance and Share Price History 

Shilpa Medicare share price on NSE and BSE reflects its position as a specialized pharmaceutical player. Performance is driven by revenue from key markets, regulatory compliance, product pipeline advancements, and profitability metrics. Investors often compare Shilpa Medicare share price today with the S&P BSE Healthcare index and peer companies to gauge relative performance. These underlying factors are often visible through real market movements across different periods. Similar trends are observed during earnings-driven movements. Broader sector dynamics have also played a role in supporting Shilpa Medicare share price. 

In addition to operational and sector-led factors, corporate actions can also have a significant impact on Shilpa Medicare share price movements short-term even when the company’s fundamentals remain strong. This shows how corporate actions can trigger short-term swings, even within a sector influenced by regulatory changes, patent cliffs, and global supply chains. While short-term movements reflect events and announcements, longer-term valuation trends are visible through Shilpa Medicare share price 52-week high and low, providing context beyond daily or weekly changes. Highs often indicate strong product demand and successful regulatory inspections, while lows align with market corrections, sector-wide pricing pressure, or company-specific challenges. These levels capture impacts of raw material costs, currency fluctuations, earnings visibility, and growth expectations, providing context for the stock’s historical performance. 

Shilpa Medicare’s stock performance reflects the trading behaviour of a pharmaceutical company operating in a competitive and regulated global environment. The company’s focus on complex generics, particularly in oncology, and its regulated market exports have shaped its Shilpa Medicare share price history. Over time, the stock has experienced periods of strong growth and phases of consolidation. The Shilpa Medicare share price reached an all-time high of ₹500 in the last year, supported by positive investor sentiment. However, the Shilpa Medicare stock price has decreased significantly from that peak. 

Over recent periods, the Shilpa Medicare share price has faced downward pressure. In the last one year, the stock declined by 32.35%, compared to gains of 8.47% for the Nifty 50. This underperformance widened over six months, with a drop of 40.83% for Shilpa Medicare against a relatively flat Nifty 50. The primary reasons for this decrease include broader underperformance in the pharmaceutical sector, which saw minimal growth, and likely company-specific factors such as margin pressures, increased competition, or delays in key product approvals that affected investor sentiment and the Shilpa Medicare share price. Despite recent declines, longer-term horizons show strength; the Shilpa Medicare stock price delivered a return of 111.87% over three years, outperforming the broader indices. However, over five and ten years, returns of 24.64% and 32.11% respectively have underperformed the Nifty 50 and the pharmaceutical sector benchmarks, indicating periods of challenge within its longer-term trajectory. Quarterly seasonality data shows volatility, with an average 5-year decline of 8.1% in Q1, strong gains of 28.6% in Q2, followed by positive and negative quarters, leading to an average annual return of 15.96%. Specific years like 2024 saw a major rally of 147.72%, while 2025 saw a decline of 21.1%, highlighting the cyclicality influencing the Shilpa Medicare share price. 

Shilpa Medicare Limited Investor Relevance and Portfolio Role 

Shilpa Medicare is a holding in healthcare-focused and small-cap portfolios, offering exposure to the API and oncology-focused formulation segments. Inclusion in indices like S&P BSE Healthcare and S&P BSE SmallCap underscores its relevance within its market segment. Its specialization in complex generics and regulatory track record make it a strategic holding for investors seeking pharmaceutical sector exposure. Shilpa Medicare equity is held by a mix of domestic and international institutional investors, reflecting its niche in the pharmaceutical sector. Top institutional stakeholders include Pivotal Enterprises Private Limited, Nippon Life India Asset Management Limited, ICICI Prudential Asset Management Company Limited, The Vanguard Group, Inc., and SBI Life Insurance Company Limited. 

Prominent mutual fund holders include Cohesion India Best Ideas (Master) Fund Limited, Elm Park Fund Limited, Bandhan Mutual Fund – Bandhan Small Cap Fund, ICICI Prudential ELSS Tax Saver Fund, and ICICI Prudential Pharma Healthcare And Diagnostics Fund. Global funds such as Vanguard Total International Stock ETF and Vanguard FTSE Emerging Markets ETF also hold stakes. This investor base highlights its role as a specialized holding in sector-specific portfolios. Technical indicators such as Shilpa Medicare RSI, MACD, and MFI provide additional insight into short-term momentum shifts in Shilpa Medicare stock price. While primarily used for near-term trading, these tools can also help gauge market sentiment and potential volatility around earnings or regulatory news. 

Shilpa Medicare’s beta indicates its volatility relative to the market. The long-term beta is 1.19, suggesting higher volatility than the market. Over shorter daily ranges, beta values are higher, such as 1.67 for a one-month range and 1.33 for a three-month range, indicating significant short-term price swings. Weekly ranges over one and two years show betas of 1.07 and 1.00 respectively, aligning closer to market volatility. Notably, the monthly two-year range beta is 2.36, pointing to substantial volatility over that specific measurement period. This beta profile suggests the Shilpa Medicare share price can experience pronounced movements, which investors factor into portfolio risk assessments. 

Shilpa Medicare Limited Sectoral Relevance and Peer Positioning 

Shilpa Medicare sector relevance stems from its specialization in oncology APIs and formulations, regulatory filings in developed markets, and vertically integrated operations, establishing it as a key player in India’s pharmaceutical manufacturing ecosystem. Peer comparisons with companies like Divi’s Laboratories, Laurus Labs, Aurobindo Pharma, Sun Pharmaceutical Industries, and Natco Pharma focus on product verticals, export market concentration, research pipeline, and manufacturing capacity rather than short-term stock moves. These benchmarks help assess operational scale, regulatory proficiency, and growth sustainability. Institutional tracking of ANDA approvals, facility inspections, margin trends, and geographic revenue mix further highlights Shilpa Medicare’s positioning within India’s broader pharmaceutical export market. 

Shilpa Medicare market cap history demonstrates its growth trajectory and market valuation changes. As of January 23, 2026, its market cap stands at ₹52.10 billion, a decrease of 17.06% from December 2025. The market cap saw a significant increase of 147.08% in 2024, reaching ₹70.86 billion, after growing 18.74% to ₹28.68 billion in 2023. In 2022, the market cap declined by 48.10% to ₹24.15 billion, following a 26.78% increase to ₹46.54 billion in 2021. Since its listing in 1999, the market cap has grown from ₹45.10 million, representing a compound annual growth rate of 30.44%. 

Shilpa Medicare earnings history shows variability in profitability over the years. Net income grew 147.11% year-on-year to ₹78.29 crore in March 2025, from ₹31.87 crore in March 2024. This followed a net loss of ₹-27.11 crore in March 2023. Earnings were ₹60.66 crore in March 2022 and a higher ₹147.78 crore in March 2021. The seven-year CAGR for net income is -4.18%, while the ten-year CAGR is 0.61%, indicating periods of pressure on bottom-line growth amidst revenue expansion and operational investments over the long term. 

Shilpa Medicare EPS mirrors its net income trajectory. EPS for March 2025 was ₹8.01, a significant recovery from ₹3.67 in March 2024 and a loss per share of ₹-3.74 in March 2023. EPS was ₹6.99 in March 2022 and peaked at ₹18.13 in March 2021. The five-year CAGR for EPS is -16.10%, and the ten-year CAGR is -1.73%. This decline in EPS over the longer term highlights the impact of increased share capital and periods of compressed profitability on per-share earnings, even as absolute net income shows a modest long-term growth rate. 

Shilpa Medicare’s P/E ratio history reflects shifting market valuations of its earnings. The latest reported P/E ratio is 37.96. For the fiscal year ending March 2025, the P/E ratio was 82.51, which was a decrease from a very high 125.49 in March 2024. The P/E ratio was negative in March 2023 due to losses. The five-year average P/E ratio is 44.01. The current trailing twelve-month P/E of 38.13 suggests a moderation in valuation compared to recent fiscal year-ends, as the market prices in earnings recovery and future growth expectations. 

Summary 

Shilpa Medicare Limited is a pharmaceutical company focused on APIs and formulations, particularly in oncology. The Shilpa Medicare share price is influenced by operational performance, regulatory developments, and sector trends. The stock is listed on NSE and BSE and is part of several indices. Its price history shows long-term growth with periods of volatility. The company is held by various institutional and mutual fund investors, and its valuation metrics like P/E and market cap reflect its evolving market position within the healthcare sector.